In glucose metabolism, inhibition of the TBK1-mediated NF-κB-MCP1 signaling pathway reduces pro-inflammatory macrophage recruitment and improves insulin resistance, resulting in efficacy in NAFLD mice [98]. This evidence concerns the gene TBK1 and metabolic dysfunction-associated steatotic liver disease.